DSSG Group: Genitourinary

Either very high-risk localised prostate cancer, or very high risk features with PSA persistence or rise within one year following radical prostatectomy, suitable for Radiotherapy.

Determine the effectiveness of adding Darolutamide to androgen deprivation therapy (ADT) and radiation therapy in either the primary definitive setting or very high risk postoperative setting.

Intermediate/high risk prostate cancer

The purpose of PACE-C is to determine whether prostate stereotactic body radiotherapy (SBRT) is non-inferior to conventional radiotherapy for freedom from biochemical/clinical failure in intermediate/high risk prostate cancer.

Metastatic hormone-sensitive prostate cancer (mHSPC) or castration-resistant prostate cancer (CRPC)

The purpose of this study is to create an international, population-based,
prospective registry of minimum 5,000 men with advanced prostate cancer.

asymptomatic or mildly symptomatic castration resistant prostate cancer patients metastatic to bone

The purpose of this study is to find out whether the combination of Xofigo® (radium-223) and Xtandi® (enzalutamide) shows better activity against Xtandi® alone (enzalutamide) in metastatic prostate cancer and if the combination of Xofigo® (radium-223) and Xtandi® (enzalutamide) is safe.

Localised intermediate risk prostate cancer

To determine if stereotactic body radiation therapy (SBRT) is superior to hypofractionated intensity modulated radiation therapy (IMRT) in the treatment of localised intermediate risk prostate cancer.

Testicular tumours that have returned.

The purpose of this trial is to compare two different doses of chemotherapy.